ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-11-10	NT$14.90	0.00%	33,272
26-11-10	NT$14.90	-0.33%	48,305
26-11-09	NT$14.95	+8.73%	95,715
26-11-06	NT$13.75	-5.82%	128,463
26-11-05	NT$14.60	-1.02%	32,852

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-11-11			5-day change	1st Jan Change
14.90 ^TWD	0.00%		-0.33%	-27.67%

10-15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
08-12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	1.15B 34.94M 31.49M 29.09M 26.3M 49.75M 3.28B 50.98M 349M 139M 1.75B 131M 128M 5.58B	P/E 2024	-11.3x	P/E 2025	-9.04x
Enterprise Value	1.1B 33.28M 29.99M 27.71M 25.05M 47.39M 3.12B 48.56M 332M 132M 1.67B 125M 122M 5.32B	EV / Sales 2024	35.4x	EV / Sales 2025	29.7x
Free-Float	28.72%	Yield 2024 *	-	Yield 2025	-

10-15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
08-12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-08	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-13	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-17	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-13	Enimmune corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-03-13	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-08-11	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-21	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-08-15	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-04-26	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-08-13	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	CI
21-04-22	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	CI

1 week	-0.33%
1 month	-9.42%
3 months	-11.83%
6 months	-21.37%
Current year	-27.67%

Enimmune corporation Stock

Stocks

6564

TW0006564008

Biotechnology & Medical Research

Valuation: Enimmune corporation

Chart: Enimmune corporation

Latest news: Enimmune corporation

Quotes and Performance

Price Extremes

Managers and Directors: Enimmune corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	13.5	15.15
1 month	13.5	16.95
Current year	13.5	22.15
1 year	13.5	22.55
3 years	13.5	49.3
5 years	13.5	75.3
10 years	13.5	125

Manager	Title	Age	Since
Che Wei Chang CEO	Chief Executive Officer	-	2019-01-06
Ching Fen Yang CTO	Chief Tech/Sci/R&D Officer	-	2014-07-20
Hung Tun Chen AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Chung Cheng Liu CHM	Chairman	-	2019-01-06
Fei Pan BRD	Director/Board Member	-	2014-01-01
Chin Yi Chiu BRD	Director/Board Member	-	2015-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENIMMUNE CORPORATION	0.00%	-0.33%	-27.67%	-58.32%	32.51M
WUXI APPTEC CO., LTD.	-1.06%	+9.92%	+59.12%	+68.61%	68.32B
ARGENX SE	+1.30%	+7.41%	+14.79%	+90.26%	60.26B
LONZA GROUP AG	+0.39%	+0.30%	+20.04%	+97.74%	55.86B
BEONE MEDICINES AG	-0.74%	+11.45%	+22.52%	+111.74%	48.43B
IQVIA HOLDINGS INC.	+0.59%	+5.10%	+26.87%	+43.15%	45.34B
REVOLUTION MEDICINES, INC.	-6.38%	-8.89%	+183.94%	+825.95%	41.76B
CELLTRION, INC.	+1.97%	+9.00%	+25.20%	+50.98%	34.5B
GENMAB A/S	-0.56%	-0.48%	+85.57%	+57.71%	33.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.49%	+13.52%	+43.09%	+0.06%	25.96B
Average	-0.60%	+4.07%	+45.35%	+128.79%	41B
Weighted average by Cap.	-0.58%	+4.03%	+50.50%	+147.62%

	2024	2025
Net sales	39.92M 1.21M 1.09M 1.01M 912K 1.73M 114M 1.77M 12.1M 4.82M 60.88M 4.55M 4.45M 194M	48.19M 1.46M 1.32M 1.22M 1.1M 2.08M 137M 2.14M 14.6M 5.82M 73.51M 5.49M 5.38M 234M
Net income	-158M -4.78M -4.31M -3.98M -3.6M -6.81M -449M -6.98M -47.74M -19.03M -240M -17.95M -17.57M -765M	-164M -4.99M -4.5M -4.16M -3.76M -7.11M -468M -7.28M -49.8M -19.85M -251M -18.73M -18.33M -798M
Net Debt	-382M -11.6M -10.45M -9.66M -8.73M -16.52M -1.09B -16.93M -116M -46.14M -583M -43.53M -42.61M -1.85B	-54.59M -1.66M -1.49M -1.38M -1.25M -2.36M -155M -2.42M -16.54M -6.59M -83.27M -6.22M -6.09M -265M